MIDLAND, TX, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $1,077,370, or $0.51 per diluted share, for the nine months ending December 31, 2024.
MIDLAND, TX, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $608,237, or $0.29 per diluted share, for the six months ending September 30, 2024.
MIDLAND, TX, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $291,039, or $0.14 per diluted share, for the quarter ending June 30, 2024, the Company's first quarter of fiscal 2025.
MIDLAND, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) reported results on its Annual Report, Form 10-K to the Securities and Exchange Commission for the fiscal year ended March 31, 2024. The Company reported net income of $1,344,952, or $0.64 per diluted share, and operating revenues of $6,604,884 for fiscal 2024.
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has been given the greenlight to develop and research new medicines in Europe with psychedelic compound psilocybin. The Slovenian Ministry of Health has opened the door for the dual-listed pharmaceuticals stock to investigate the psychedelic compound's physical and chemical properties and develop pharmaceutical forms suitable for administration.